All News

RheumNow Podcast square

RheumNow Podcast – Saphnelo (Anifrolumab) Approved for Lupus (8.6.2021)

Jack Cush, MD

It was a banner week at the FDA; a new drug approval you should know about; a lot of information about pregnancy and safety; and an interesting case plus a question from one of our readers submitted via Back Talk. This and more in this week's podcast. Let's dive in.

Read Article
myositis, polymyositis, wikipedia

Skin Involvement with HMGCR Necrotizing Myositis

Jack Cush, MD

The Journal of Autoimmunity reports that anti-HMRCR antibody positive, necrotizing myositis patients frequently have cutaneous lesions, moreso than previously reported.

Read Article
covid vaccine

Rheumatic Flares Uncommon After COVID Vax

MedPage Today

Post-vaccination disease flares were uncommon among patients with rheumatic and musculoskeletal diseases who were inoculated against COVID-19, researchers found.

Read Article
FDA.approved.jpg

FDA Approves Anifrolumab in SLE

Jack Cush, MD

AstraZeneca announced today that anifrolumab (Saphnelo or anifrolumab-fnia) was approved by the the Food and Drug Administration (FDA) for that treatment of adult patients with moderate to severe systemic lupus erythematosus (SLE) who are receiving standard therapy.  

Read Article
RheumNow Podcast square

RheumNow Podcast – Psoriatic Arthritis Without Psoriasis (7.30.2021)

Jack Cush, MD

How much psoriasis do you need to have in order to have psoriatic arthritis? This plus a review of rheumatology and COVID news from the past week on RheumNow.com.

Read Article
shingles_0.jpg

Shingles Risk with JAK Inhibitors and Other Biologics

Jack Cush, MD

Registry data suggests an increased risk of herpes zoster (HZ, shingles) in rheumatoid arthritis (RA) patients taking JAK inhibitors (JAKi) but also with other biologic DMARDs, compared to csDMARDs.

Read Article
syringe, pill, DMARD, Treatment, therapy

DMARD Effects on COVID-19 Outcomes

Jack Cush, MD

Sparks and colleagues have published data from the Global Rheumatology Alliance noting that among rheumatoid arthritis (RA) patients afflicted with COVID-19 infection, there was little influence of their baseline biologic or targeted synthetic (b/ts) disease-modifying antirheumatic drug

Read Article
hip, OA, AVN

Osteonecrosis in Lupus

Jack Cush, MD

A single center analysis of systemic lupus erythematosus (SLE) patients found symptomatic osteonecrosis (ON) in nearly 10%.

Read Article
Drs. Jack Cush, Kathryn Dao, Janet Pope, Eric Dein and Yuz Yusof discuss a number of lupus presentations as well as abstracts presented at the virtual EULAR 2021 meeting. Lupus nephritis and treat-to-remission presentations were discussed by the panel. https://t.co/dfRdeveeLp

Links:

Dr. John Cush RheumNow ( View Tweet)

In 206 #SLE pts (mean 62 yrs) polypharmacy (≥10 meds) seen in 35%. 31% used benzodiazepines & 24% opioids. Polypharmacy greater with prednisone, comorbidity & rural. Polypharmacy assoc w/ 4X Benzo & 7X opioid use https://t.co/4U0UakoIRr

Links:

Dr. John Cush RheumNow ( View Tweet)

It was a banner week at the FDA; a new drug approval you should know about; a lot of information about pregnancy and safety; and an interesting case plus a question from one of our readers--this and more in this week's podcast. Let's dive in. https://t.co/5K8ejJ4jj2 https://t.co/RDEM0BMZLC

Links:

Dr. John Cush RheumNow ( View Tweet)
FDA Approves Anifrolumab in active, moderate-severe SLE on background standard of care therapies. https://t.co/22HVA32IAh https://t.co/NxJ4sWTWfE

Links:

Dr. John Cush RheumNow ( View Tweet)

ICYMI: Belimumab now approved in the EU for lupus nephritis. The EMA has approved intravenous and subcutaneous Benlysta (belimumab) in combination with background immunosuppressive therapies for adults with active lupus nephritis https://t.co/Twbe1ClT5w

Links:

Dr. John Cush RheumNow ( View Tweet)

Claims data analysis of US Adult Medicaid patients shows and association between PTSD and increased risk of #SLE. 10K SLE compared to >100K controls. Prevalence of PTSD was significantly higher in SLE (10.74 vs 7.83 per 1000 (adj OR 2.0) https://t.co/p9F5iYENAu

Links:

Dr. John Cush RheumNow ( View Tweet)

CMAJ: nice full read review of biologic use during pregnancy. 1) autoimmune/arthritis pts may use biologics during pregnancy 2) mom/infant should avoid live vax 1st 6–12 mos 3) Minimal biologic transfer in breast milk 4) no risk of congenital anomalies https://t.co/mlZTrDjXSi

Links:

Dr. John Cush RheumNow ( View Tweet)

ICYMI: Neuropsychiatric Events Common in Lupus Neuropsychiatric (NP-SLE) or CNS lupus events range from mild to severe; several recent studies have noted that NPS lupus is common and should be screened for. https://t.co/cBDZI8OLKD https://t.co/on4fA3P9GS

Links:

Dr. John Cush RheumNow ( View Tweet)
#ClinicalPearl Palmar erythema in #SLE #lupus is sometimes painful, may not be fixed and also may have erythema of distal fingers on flexor side https://t.co/C5mysB8pFS
Janet Pope Janetbirdope ( View Tweet)
Top Tweet Last Week: Potential Birth Defects with Hydroxychloroquine HCQ is one of the safest meds used in rheumatology, but there is new claims data suggesting a small increase in the risk of malformations associated with first-trimester HCQ use. https://t.co/IHNKjHVXaU https://t.co/Oay2ayVr9m

Links:

Dr. John Cush RheumNow ( View Tweet)
Osteonecrosis in Lupus A single center analysis of systemic lupus erythematosus (SLE) patients found symptomatic osteonecrosis (ON) in nearly 10%. https://t.co/PoVsm6TYT1 https://t.co/MTeTiUXDS4

Links:

Dr. John Cush RheumNow ( View Tweet)
NEJM posts images of the malar rash, typical of #SLE. https://t.co/YZsnAXyhVX

Links:

Dr. John Cush RheumNow ( View Tweet)

How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×